Search

Your search keyword '"Severi, Gianluca"' showing total 146 results

Search Constraints

Start Over You searched for: Author "Severi, Gianluca" Remove constraint Author: "Severi, Gianluca" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
146 results on '"Severi, Gianluca"'

Search Results

1. Plasma levels of OPN (ng/ml) in HCC Cases and matched Controls. from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

2. Data from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

3. Supplementary Figures Legends from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

4. Cubic spline for the association between OPN levels and HCC from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

5. Supplementary Tables from Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

6. Appendix from Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk

7. Supplementary Materials and Methods from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

8. Data from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

9. Supplementary Figure Legends from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

10. Data from Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer

11. Evaluation of added discriminatory ability from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

12. Spearman coefficients of correlation from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

13. Supplementary Tables 1 through 8 and Supplementary Figures 1 through 15 from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

14. Supplementary Table 1 from Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk

15. Supplementary Table 2 from Leukocyte Telomere Length in Relation to Pancreatic Cancer Risk: A Prospective Study

16. Supplementary Table 1 from Leukocyte Telomere Length in Relation to Pancreatic Cancer Risk: A Prospective Study

17. Data from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

18. Data from 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

19. Supplementary Figure 1 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

20. Supplementary Tables 1-8 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

21. Supplementary Table 3 from 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

22. Data from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer

23. Supplementary Figure 1 from Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk

24. Supplementary Table 3 from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer

25. Supplementary Figure 1 from Leukocyte Telomere Length in Relation to Pancreatic Cancer Risk: A Prospective Study

26. Supplementary Table 2 from 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

27. Supplementary Table Legend from 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

28. Supplementary Figure S2 from Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies

29. ROC curves and C-statistics by tumor stage from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

30. Supplementary Table 1 from 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

31. Supplementary Data from Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer

32. Supplementary Table 1 from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer

33. C-statistics by tumor histology from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

34. Supplementary Notes from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

35. Supplementary Figure 3 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

36. Supplementary Table 2 from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer

37. Supplementary Figure 1 from Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)

38. Supplementary Material from KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case–Control Study

39. Supplementary Tables 1-8 from Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)

40. Supplementary Table 4 from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer

41. Supplemental Tables 1-3 from Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort

42. Case characteristics from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

43. Supplementary Figure 2 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

44. Supplementary Table S1 from Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies

45. Data from Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

46. Data from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease

47. Data from Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10

48. Data from 19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus

49. Supplementary Tables 1 - 5 from Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10

50. Supplementary Materials and Methods, Tables 1-5 from Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

Catalog

Books, media, physical & digital resources